Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16945673 | 1.00 | NOS1 (0.45) | NOS1ELANE | |
| SCHEMBL12446838 | 1.00 | NOS1 (0.45) | NOS1ELANE | |
| SCHEMBL8208552 | 0.85 | NOS1 (0.43) | NOS1ELANE | |
| SCHEMBL12062416 | 0.83 | ELANE (0.36) | NOS1ELANE | |
| SCHEMBL12062418 | 0.83 | ELANE (0.36) | NOS1ELANE | |
| SCHEMBL7827758 | 0.83 | NOS1 (0.36) | NOS1ELANE | |
| SCHEMBL7827757 | 0.83 | NOS1 (0.36) | NOS1ELANE | |
| SCHEMBL17560599 | 0.83 | NOS1 (0.36) | NOS1ELANE | |
| SCHEMBL14936428 | 0.83 | NOS1 (0.49) | NOS1ELANE | |
| SCHEMBL12447518 | 0.79 | ELANE (0.33) | NOS1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036560-A | Radioactive medical isotope18F-labeled norepinephrine analogue as well as preparation method and application thereof | 中国医学科学院阜外医院 | 2026-05-15 | — | — | CN | claimed |
| CN-122036560-A | Radioactive medical isotope18F-labeled norepinephrine analogue as well as preparation method and application thereof | 中国医学科学院阜外医院 | 2026-05-15 | — | — | CN | disclosed |
| US-12415828-B2 | Modified oligonucleotides and methods for their synthesis | NOOGEN LLC (RU) | 2025-09-16 | — | — | US | disclosed |
| CN-114907301-B | Ranitivir octanoate intermediate and preparation method thereof | 上海医药工业研究院 | 2024-05-28 | — | — | CN | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| CN-117396465-A | Novel oxazole derivative for preventing or treating allergic diseases and pharmaceutical composition containing the same | 阿斯克里斯有限公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023199881-A1 | METHOD FOR PRODUCING SEMICONDUCTOR SUBSTRATE AND RESIST UNDERLAYER FILM FORMING COMPOSITION | JSR株式会社 | 2023-10-19 | — | — | WO | disclosed |
| CN-111562720-B | Photo-sensitized chemically amplified resist material, pattern forming method, semiconductor device, mask for lithography, and template for nanoimprint | 东京毅力科创株式会社 | 2023-09-29 | — | — | CN | disclosed |
| CN-111116533-B | Zanamivir and ranamivir intermediate and synthesis method thereof | 中国科学院上海有机化学研究所 | 2022-11-22 | — | — | CN | disclosed |
| CN-114907301-A | Ranitivir caprylate intermediate and preparation method thereof | 上海医药工业研究院 | 2022-08-16 | — | — | CN | disclosed |
| WO-2004067521-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2004-08-12 | — | — | WO | disclosed |
| EP-1442027-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-08-04 | — | — | EP | disclosed |
| CN-1419546-A | 4, 5-dihydro-1H-pyrazole derivatives having CB 1-antagonistic activity | SOLVAY PHARM BV (NL) | 2003-05-21 | — | — | CN | disclosed |
| WO-2003031419-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| US-6476060-B2 | DRUG ABUSE; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS; CARDIOVASCUALR DISORDERS | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2002-11-05 | — | — | US | disclosed |
| US-20010053788-A1 | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2001-12-20 | — | — | US | disclosed |
| EP-1037668-A1 | TRANSFECTION PARTICLES | Boehringer Ingelheim International GmbH (DE) | 2000-09-27 | — | — | EP | disclosed |
| EP-0945138-A1 | Transfection particles | Université Louis Pasteur de Strasbourg (FR) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999029349-A1 | TRANSFECTION PARTICLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 1999-06-17 | — | — | WO | disclosed |
| EP-0743320-A2 | Acyl guanidine and amidine prodrugs | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053788-A1 | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | CNR1, CNR2, CBR3 | NOS1 3155/4885ELANE 3992/4885 |
| US-12415828-B2 | Modified oligonucleotides and methods for their synthesis | RNGTT, TYMP, POLM | NOS1 4361/4885ELANE 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.